{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:33:41Z","timestamp":1775136821782,"version":"3.50.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>IMPORTANCE:<\/jats:title>\n            <jats:p>Sepsis and septic shock are major healthcare problems that need early and appropriate management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>To evaluate the association of daily cefepime pharmacokinetic\/pharmacodynamic (PK\/PD) parameters with change in Sequential Organ Failure Assessment (SOFA) score and vasopressors requirement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN, SETTING, AND PARTICIPANTS:<\/jats:title>\n            <jats:p>This is a retrospective study. Adult ICU patients who received cefepime for Gram-negative pneumonia or bloodstream infection (BSI) and had cefepime concentrations measured were included. Daily cefepime exposure was generated and PK\/PD parameters calculated for patients. Repeated-measures mixed-effect modeling was used to evaluate the impact of PK\/PD on the outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOMES AND MEASURES:<\/jats:title>\n            <jats:p>Change in daily SOFA score and vasopressors requirement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>A total of 394 and 207 patients were included in the SOFA and vasopressors analyses, respectively. The mean (\u00b1<jats:sc>sd<\/jats:sc>) age was 55 years (19) and weight 81\u2009kg (29). For the change in SOFA score, daily SOFA score, mechanical ventilation, renal replacement therapy, and number of vasopressors were included. In the vasopressors analysis, daily SOFA score, day of therapy, and hydrocortisone dose were significant covariates in the final model. Achieving cefepime concentrations above the minimum inhibitory concentration (MIC) (T<jats:sub>&gt;MIC<\/jats:sub>) for 100% of the dosing interval was associated with 0.006 \u00b5g\/kg\/min decrease in norepinephrine-equivalent dose. Cefepime PK\/PD did not have an impact on the daily change in SOFA score.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS AND RELEVANCE:<\/jats:title>\n            <jats:p>Achieving 100% T<jats:sub>&gt;MIC<\/jats:sub> was associated with negligible decrease in vasopressors requirement in ICU patients with Gram-negative pneumonia and BSI. There was no impact on the change in SOFA score.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000000993","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T14:00:40Z","timestamp":1698674440000},"page":"e0993","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Cefepime Daily Exposure and the Associated Impact on the Change in Sequential Organ Failure Assessment Scores and Vasopressors Requirement in Critically Ill Patients Using Repeated-Measures Mixed-Effect Modeling"],"prefix":"10.1097","volume":"5","author":[{"given":"Mohammad H.","family":"Alshaer","sequence":"first","affiliation":[{"name":"Infectious Disease Pharmacokinetics Laboratory, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL."},{"name":"Emerging Pathogens Institute, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Williams","sequence":"additional","affiliation":[{"name":"Emerging Pathogens Institute, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mays J.","family":"Mousa","sequence":"additional","affiliation":[{"name":"Infectious Disease Pharmacokinetics Laboratory, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlin M.","family":"Alexander","sequence":"additional","affiliation":[{"name":"Emerging Pathogens Institute, University of Florida, Gainesville, FL."},{"name":"Department of Pharmacy, UF Health Shands Hospital, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly L.","family":"Maguigan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UF Health Shands Hospital, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayihura","family":"Manigaba","sequence":"additional","affiliation":[{"name":"Emerging Pathogens Institute, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Maranchick","sequence":"additional","affiliation":[{"name":"Infectious Disease Pharmacokinetics Laboratory, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL."},{"name":"Emerging Pathogens Institute, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany R.","family":"Shoulders","sequence":"additional","affiliation":[{"name":"Emerging Pathogens Institute, University of Florida, Gainesville, FL."},{"name":"Department of Pharmacy, UF Health Shands Hospital, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy W.","family":"Felton","sequence":"additional","affiliation":[{"name":"North West Ventilation Unit, Manchester University NHS Foundation Trust, Manchester, United Kingdom."},{"name":"Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumith K.","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[{"name":"Infectious Disease Pharmacokinetics Laboratory, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL."},{"name":"Emerging Pathogens Institute, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"R1-20240806","doi-asserted-by":"crossref","first-page":"e187571","DOI":"10.1001\/jamanetworkopen.2018.7571","article-title":"Prevalence, underlying causes, and preventability of sepsis-associated mortality in US acute care hospitals.","volume":"2","author":"Rhee","year":"2019","journal-title":"JAMA network open"},{"key":"R3-20240806","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1378\/chest.101.6.1656","article-title":"Evaluation of definitions for sepsis.","volume":"101","author":"Knaus","year":"1992","journal-title":"Chest"},{"key":"R4-20240806","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Emerging infections program healthcare-associated infections and antimicrobial use prevalence survey team. Multistate point-prevalence survey of health care-associated infections.","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"R5-20240806","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/664049","article-title":"Economic impact of ventilator-associated pneumonia in a large matched cohort.","volume":"33","author":"Kollef","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R6-20240806","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1086\/653060","article-title":"Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia.","volume":"51","author":"Muscedere","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R7-20240806","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s00134-020-05980-0","article-title":"Ventilator-associated pneumonia in adults: A narrative review.","volume":"46","author":"Papazian","year":"2020","journal-title":"Intensive Care Med"},{"key":"R8-20240806","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"R9-20240806","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S1473-3099(13)70081-1","article-title":"Attributable mortality of ventilator-associated pneumonia: A meta-analysis of individual patient data from harmacome prevention studies.","volume":"13","author":"Melsen","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"R10-20240806","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1128\/AAC.01183-09","article-title":"Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.","volume":"54","author":"Crandon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20240806","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: Defining antibiotic levels in intensive care unit patients: Are current b-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R12-20240806","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40265-018-0891-9","article-title":"Individualising therapy to minimize bacterial multidrug resistance.","volume":"78","author":"Heffernan","year":"2018","journal-title":"Drugs"},{"key":"R13-20240806","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure.","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"R14-20240806","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jcrc.2021.05.017","article-title":"Vasopressor and inotrope treatment for septic shock: An umbrella review of reviews.","volume":"65","author":"Einav","year":"2021","journal-title":"J Crit Care"},{"key":"R15-20240806","doi-asserted-by":"crossref","first-page":"e0056322","DOI":"10.1128\/aac.00563-22","article-title":"Using machine learning to define the impact of beta-lactam early and cumulative target attainment on outcomes in intensive care unit patients with hospital-acquired and ventilator-associated pneumonia.","volume":"66","author":"Alshaer","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-20240806","doi-asserted-by":"crossref","first-page":"106727","DOI":"10.1016\/j.ijantimicag.2023.106727","article-title":"Beta-lactam target attainment and associated outcomes in patients with bloodstream infections.","volume":"61","author":"Alshaer","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"R17-20240806","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jcrc.2020.11.002","article-title":"Vasopressor dose equivalence: A scoping review and suggested formula.","volume":"61","author":"Goradia","year":"2021","journal-title":"J Crit Care"},{"key":"R18-20240806","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/FTD.0000000000000675","article-title":"Meropenem, cefepime, and piperacillin protein binding in patient samples.","volume":"42","author":"Al-Shaer","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R19-20240806","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":"Accurate detection of outliers and subpopulations with Pmetrics, a non-parametric and parametric harmacometrics modeling and simulation package for R.","volume":"34","author":"Neely","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R20-20240806","first-page":"AAC-02046","article-title":"Cefepime precision dosing tool: From standard to precise dose using nonparametric population pharmacokinetics.","volume":"66","author":"Alshaer","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-20240806","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models Usinglme4.","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Soft"},{"key":"R22-20240806","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12874-019-0847-0","article-title":"Incorporating repeated measurements into prediction models in the critical care setting: A framework, systematic review and meta-analysis.","volume":"19","author":"Plate","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"R23-20240806","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-017-1609-1","article-title":"SOFA and mortality endpoints in randomized controlled trials: A systematic review and meta-regression analysis.","volume":"21","author":"de Grooth","year":"2017","journal-title":"Crit Care"},{"key":"R24-20240806","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","article-title":"Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: A randomized controlled trial.","volume":"48","author":"Hagel","year":"2022","journal-title":"Intensive Care Med"},{"key":"R25-20240806","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s00134-022-06654-9","article-title":"Another trial for the TARGET trial.","volume":"48","author":"Alshaer","year":"2022","journal-title":"Intensive Care Med"},{"key":"R26-20240806","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijantimicag.2017.04.023","article-title":"Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: A \u201cGoldilocks\u201d window.","volume":"50","author":"Miglis","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R27-20240806","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy.","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R28-20240806","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/antibiotics10060687","article-title":"Prolonged infusion of \u03b2-lactams decreases mortality in patients with septic shock: A retrospective before-and-after study.","volume":"10","author":"Richter","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"R29-20240806","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/0885066618784264","article-title":"Evaluation of meropenem extended versus intermittent infusion dosing protocol in critically ill patients.","volume":"35","author":"Ahmed","year":"2020","journal-title":"J Intensive Care Med"},{"key":"R30-20240806","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R31-20240806","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of \u03b2-lactams, glycopeptides, and linezolid.","volume":"17","author":"Craig","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"R32-20240806","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/jac\/dkx001","article-title":"Determining \u03b2-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.","volume":"72","author":"Tam","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R33-20240806","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1128\/AAC.01956-15","article-title":"Defining clinical exposures of cefepime for Gram-negative bloodstream infections that are associated with improved survival.","volume":"60","author":"Rhodes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R34-20240806","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","article-title":"Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.","volume":"42","author":"Abdul-Aziz","year":"2016","journal-title":"Intensive Care Med"},{"key":"R35-20240806","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T> MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:01:03Z","timestamp":1722988863000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000993","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]}}}